New therapeutic strategies for type 2 diabetes : small molecule approaches /
Jones, Robert M.(Robert Mark)
Royal Society of Chemistry (Great Britain)
Cambridge : RSC Publishing,
c2012.
Includes bibliographical references and index.
Type 2 diabetes: disease overview / Daniel M. Kemp -- Marketed small molecule dipeptidyl peptidase IV (DPP4) inhibitors as a new class of oral anti-diabetics / Zhonghua Pei -- SGLT2 inhibitors in development / William N. Washburn -- Glucokinase activators in development / Kevin J. Filipski, Benjamin D. Stevens and Jeffrey A. Pfefferkorn -- 11[beta]-hydroxysteroid dehydrogenase type 1 (11[beta]-HSD1) inhibitors in development / James S. Scott and Jasen Chooramun -- Recent advances in PTP1B inhibitor development for the treatment of type 2 diabetes and obesity / Rongjun He, Li-Fan Zeng, Yantao He and Zhong-Yin Zhang -- Recent advances in the discovery of GPR119 agonists / Unmesh Shah, Scott Edmondson and Jason W. Szewczyk -- Acyl-CoA: diacylglycerol acyltransferase-1 inhibition as an approach to the treatment of type 2 diabetes / Robert L. Dow -- Stearoyl-CoA desaturase 1 (SCD1) inhibitors: bench to bedside must only go through liver / Gang Liu -- TGR5 agonists in development / Antonio Macchiarulo, Antimo Gioiello and Roberto Pellicciari -- The discovery and development of MB07803, a second generation fructose-1,6-bisphosphatase inhibitor with improved pharmacokinetic properties, as a potential treatment of type 2 diabetes / Qun Dang, Paul D. van Poelje and Mark D. Erion -- Inhibition of glycogen phosphorylase as a strategy for the treatment of type 2 diabetes / Brad R. Henke -- SIRT1 activators in development / Robert B. Perni ... [et al.] -- Long-chain free fatty acid receptor agonists / Jonathan B. Houze -- Glucagon receptor antagonists in development / Duane E. DeMong and M. W. Miller -- ACC inhibitors in development / Matthew P. Bourbeau.
Diabetes